Cargando…
High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
Alzheimer’s disease (AD) is the most common form of cognitive decline worldwide, occurring in about 10% of people older than 65 years. The well-known hallmarks of AD are extracellular aggregates of amyloid β (Aβ) and intracellular neurofibrillary tangles (NFTs) of tau protein. The evidence that Aβ o...
Autores principales: | Bivona, Giulia, Iemmolo, Matilda, Piccoli, Tommaso, Agnello, Luisa, Lo Sasso, Bruna, Ciaccio, Marcello, Ghersi, Giulio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571188/ https://www.ncbi.nlm.nih.gov/pubmed/36233371 http://dx.doi.org/10.3390/jcm11195498 |
Ejemplares similares
-
CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease
por: Bivona, Giulia, et al.
Publicado: (2023) -
The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases
por: Iemmolo, Matilda, et al.
Publicado: (2023) -
Microglial Activation and Priming in Alzheimer’s Disease: State of the Art and Future Perspectives
por: Bivona, Giulia, et al.
Publicado: (2023) -
COVID-19 and Alzheimer’s Disease
por: Ciaccio, Marcello, et al.
Publicado: (2021) -
Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease
por: Agnello, Luisa, et al.
Publicado: (2021)